ASSOCIATION OF ADIPONECTIN WITH TOTAL LEUKOCYTE COUNT IN PATIENTS OF CORONARY ARTERY DISEASE
AbstractBackground: Hypoadiponectinemia and raised total leukocyte count have been associated with coronary artery disease. The aim of this study was to investigate association of serum adiponectin levels with total leukocyte count in patients of coronary artery disease belonging to Khyber Pakhtunkhwa. Methods: This cross-sectional/analytical study consisted of two groups. Group A contained 100 patients of coronary artery disease while group B contained 100 healthy controls. Consent of the study subjects was obtained, their history was recorded and fasting blood samples were analyzed for serum adiponectin level, total leukocyte count (TLC), serum lipid profile which included serum total cholesterol (T-C), triglyceride level (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C). Adiponectin level was determined with ELIZA method, TLC was estimated on automated hematology analyzer and lipid profile was determined using enzymatic colorimetric method. SPSS version 21 was used to analyze the data. Results: Subjects with coronary artery disease when compared to healthy subjects showed significantly high level of total leukocyte count (9.26±1.488 vs. 6.37±4.052) and low level of serum adiponectin (4.3±0.80 vs. 9.6±3.69). Moreover, serum lipid profile showed low HDL-C (30.04±9.1 vs. 43.64±7.3) and raised triglyceride (220.1±67.7 vs. 181.86±41.4), total cholesterol (229.3±37.01 vs. 189.4±32.7), and LDL-C (153.78±38.53 vs. 109.16±33.91) levels. Significant negative association of adiponectin with TLC (r -0.826 with p<0.01) was observed in the study subjects. Conclusion: We observed elevated level of total leukocyte count and reduced level of adiponectin in subjects with coronary artery disease. Moreover, hypoadiponectinemia correlated negatively with TLC levels.
Song P, Fang Z, Wang H, Cai Y, Rahimi K, Zhu Y, et al. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. Lancet Glob Health 2020;8(5):e721–9.
Kim H, Kim S, Han S, Rane PP, Fox KM, Qian Y, et al. Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study. BMC Public Health 2019;19(1):1112.
Ambrose JA, Singh M. Pathophysiology of coronary artery disease leading to acute coronary syndrome. F1000Prime Rep 2015;7:1–8.
Salehi N, Eskandarian R, Sanati HR, Firouzi A, Shakerian F, Abdi S, et al. White blood cell count and mortality in acute myocardial infarction. World J Cardiovas Dis 2013;3(7):458–63.
Welsh C, Welsh P, Mark PB, Celis-Morales CA, Lewsey J, Stuart R, et al. Association of total and differential leukocyte counts with cardiovascular disease and mortality in the UK Biobank. Arterioscler Thromb Vasc Biol 2018;38(6);1415–23.
Khoramipour K, Chamari K, Hekmatikar AA, Ziyaiyan A, Taherkhani S, Elguindy NM, et al. Adiponectin: structure, physiological functions, role in diseases, and effects of nutrition. Nutrients 2021;13(4):1180.
Nagaraju GP, Rajitha B, Aliya S, otipatruni RP, Madanrai AS, Hammond A, et al. The role of adiponectin in obesity associated female-specific carcinogenesis. Cytokine Growth Factor Rev 2016;3:37–48.
Horakova D, Azeem K, Benesova R, Pastucha D, Horak V, Dumbrovska L, et al. Total and high molecular weight adiponectin levels and prediction of cardiovascular risk in diabetic patients. J Int Endocrinol 2015;2015:545068.
Rajkovic N, Zamaklar M, Lalic K, Jotic A, Lukic L, Milicic T, et al. Relationship between obesity, adipocytokines and inflammatory markers in type 2 diabetes: relevance for cardiovascular risk prevention. Int J Environ Res Public Health 2014;11(4):4049–65.
Foucan L, Maimaitiming S, Larifla L, Hedreville S, Deloumeaux J, Joannes MO, et al. Adiponectin gene variants, adiponectin isoforms and cardiometabolic risk in type 2 diabetic patients. J Diabetes Invest 2014;5(2):192–8.
Friedwald WT, Levy PI, Fredrickson DS. Estimation of concentration of low density lipoprotein cholesterol in plasma, without use of the preparative centrifuge. Clin Chem 1972;18(6):449–502.
Welsh P, Grassia G, Botha S, Sattar N, Maffia P. Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect? Br J Pharmacol 2017;174:3898–913.
Bäck M, Hansson GK. Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol 2015;12(4):199–211.
Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999;340(2):115–26.
Ferrari JP, Lueneberg ME, Silva RL, Fattah T, Gottschall CAM, Moreira DM. Correlation between leukocyte count and infarct size in ST segment elevation myocardial infarction. Arch Med Sci Atheroscler Dis 2016;1(1):44–8.
Kabat GC, Kim MY, Manson JE, Lessin L, Lin J, Wassertheil-Smoller S, et al. White blood cell count and total and cause-specific mortality in the women’s health initiative. Am J Epidemiol 2017;186(1):63–72.
Friedman GD, Klatsky AL, Siegelaub AB. The leukocyte count as a predictor of myocardial infarction. N Engl J Med 1974;290:1275–8.
Budzianowski J, Pieszko K, Burchardt P, Rzeźniczak J, Hiczkiewicz J. The role of hematological indices in patients with acute coronary syndrome. Dis Markers
Laurie GF, Lamberg L. The leukocyte count, a measure and predictor of coronary events. Am J Crit Care 2007;16:401–4.
Madjid M, Awan I, Willerson JT, Casscells W. Leukocyte count and coronary heart disease. J Am Coll Cardiol 2004;44(10):1945–56.
Wang T, Jiang CJ, Xu L, Zhang WS, Zhu F, Jin YL, et al. White blood cell count and all-cause and cause-specific mortality in the Guangzhou biobank cohort study. BMC Public Health 2018;18(1):1232.
Roig CS, Braster Q, Ortega-Gomez A, Soehnlein O. Neutrophils as regulators of cardiovascular inflammation. Nat Rev Cardiol 2020;17(6):327–40.
Ndrepepag G, Brauns S, Iijimar R, Keta D, Byrner A, Schulz S, et al. Total leucocyte count, but not C-reactive protein, predicts 1-year mortality in patients with acute coronary syndromes treated with percutaneous coronary intervention. Clin Sci (Lond) 2009;116(8):651–58.
Majid M. Components of the complete blood count as predictors for coronary heart disease. Tex Heart Inst J 2013;40(1):17–29.
Jan AF, Habib S, Naseeb K, Khatri MA, Zaman KS. High Total leukocyte count and heart failure after myocardial infarction. Pak Heart J 2011;44(1-2):8–17.
Grau AJ, Boddy AW, Dukovic DA, Buggle F, Lichy C, Brandt T, et al. Leukocyte count as an independent predictor of recurrent ischemic events. Stroke 2004;35(5):1147–52.
Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350(14):1387–97.
Liang S, Li H, Shen X, Liu R. Increased serum adiponectin predicts improved coronary flow and clinical outcomes in patients with ST‐segment elevation myocardial infarction treated by primary percutaneous coronary intervention. J Clin Lab Anal 2019;33(5):e22864.
Giannessi D, Caselli C, Ry SD, Maltinti M, Pardini S, Turchi S, et al. Adiponectin is associated with abnormal lipid profile coronary microvascular dysfunction in patients with dilated cardiomyopathy without overt heart failure. Metabolism 2011;60(2):227–33.
Rasmussen S, Olsen F, Pedersen S, Lindberg S, Nochioka K, Magnusson N, et al. A multiple biomarker approach for risk assessment after ST-segment elevation myocardial infarction. Eur Heart J 2019;40(1):ehz745–1010.
Woodward L, Akoumianakis I, Antoniades C. Unravelling the adiponectin paradox: Novel roles of adiponectin in the regulation of cardiovascular disease. Br J Pharmacol 2017;174:4007–20.
Trifunovic D, Stankovic S, Marinkovic J, Beleslin B, Banovik M, Djukanovic N. Time-dependent changes of plasma adiponectin concentration in relation to coronary microcirculatory function in patients with acuete myocardial infarction treated by primary percutaneous coronary intervention. J Cardiol 2015;65(3):208–15.
Wu Z, Cheng Y, Aung LHH, Li B. Association between adiponectin concentrations and cardiovascular disease in diabetic patients: A systematic review and meta-Analysis. PLoS One 2013;8(11):e78485.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.